COMMUNIQUÉ DE PRESSE publié le 18/03/2024 à 10:00, il y a 2 années 3 mois Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada Formycon and Fresenius Kabi reach settlement agreement with Johnson & Johnson for ustekinumab biosimilar FYB202 in Europe and Canada. Agreement terms kept confidential. Focus on expanding patient access and ensuring reliable treatment options Settlement Agreement Biosimilar Formycon Fresenius Kabi Ustekinumab
BRÈVE publiée le 11/03/2024 à 07:35, il y a 2 années 3 mois FYB201/Ranibizumab Gains Approval and Scheduled for Launch in the MENA Region MENA Region Formycon AG MS Pharma Ranibizumab Diabetic Retinopathies
BRÈVE publiée le 11/03/2024 à 07:35, il y a 2 années 3 mois FYB201/Ranibizumab obtient l'approbation et son lancement est prévu dans la région MENA Formycon AG MS Pharma Ranibizumab Région MENA Rétinopathies Diabétiques
COMMUNIQUÉ DE PRESSE publié le 11/03/2024 à 07:30, il y a 2 années 3 mois FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region Formycon AG and MS Pharma announce the approval and market launch of FYB201/Ranibizumab in the MENA region, with plans for commercialization in Saudi Arabia and other countries in 2024 MENA Region Formycon AG MS Pharma FYB201/Ranibizumab Biosimilar
COMMUNIQUÉ DE PRESSE publié le 29/01/2024 à 22:15, il y a 2 années 4 mois Gedeon Richter becomes strategic investor of Formycon via equity investment Formycon AG announces strategic investment from Gedeon Richter, leading to a 9.08% equity takeover via cash capital increase of EUR 82.84 million. The investment will ensure high development pace and operational progress Pharmaceutical Industry Formycon AG Gedeon Richter Equity Investment Biosimilars
COMMUNIQUÉ DE PRESSE publié le 29/01/2024 à 22:10, il y a 2 années 4 mois EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor Formycon AG resolves on EUR 82.84 million cash capital increase by issuing 1,603,877 new shares, all subscribed by Gedeon Richter as strategic investor. Proceeds for biosimilar pipeline development. New shares to be traded on Frankfurt Stock Exchange Frankfurt Stock Exchange Formycon AG Cash Capital Increase Gedeon Richter Biosimilar Pipeline
COMMUNIQUÉ DE PRESSE publié le 10/11/2023 à 06:30, il y a 2 années 7 mois Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
COMMUNIQUÉ DE PRESSE publié le 10/10/2023 à 07:30, il y a 2 années 8 mois Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
COMMUNIQUÉ DE PRESSE publié le 29/09/2023 à 07:30, il y a 2 années 8 mois Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
COMMUNIQUÉ DE PRESSE publié le 30/08/2023 à 07:30, il y a 2 années 9 mois Formycon reports successful first half of 2023
Publié le 19/06/2026 à 19:33, il y a 3 heures 36 minutes Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Publié le 19/06/2026 à 19:33, il y a 3 heures 36 minutes Disclosure of transactions in own shares from June 15 to June 19, 2026
Publié le 19/06/2026 à 19:23, il y a 3 heures 45 minutes Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Publié le 19/06/2026 à 19:23, il y a 3 heures 45 minutes Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Publié le 19/06/2026 à 04:30, il y a 18 heures 39 minutes Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Publié le 19/06/2026 à 01:20, il y a 21 heures 49 minutes American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Publié le 19/06/2026 à 01:07, il y a 22 heures 2 minutes Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Publié le 19/06/2026 à 00:00, il y a 23 heures 9 minutes Redwood AI Announces Initiation of Chemical Risk Assessment Module
Publié le 19/06/2026 à 20:17, il y a 2 heures 51 minutes 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Publié le 19/06/2026 à 20:17, il y a 2 heures 51 minutes 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Publié le 19/06/2026 à 19:01, il y a 4 heures 7 minutes Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting